| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99284 |
Emergency department visit for the evaluation and management, high severity |
9,479 |
7,890 |
$7.85M |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
46,275 |
39,114 |
$6.26M |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
45,547 |
38,446 |
$4.38M |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
24,082 |
19,286 |
$4.17M |
| 96413 |
Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance |
7,876 |
3,714 |
$3.42M |
| 76818 |
|
12,995 |
4,325 |
$3.27M |
| 87624 |
Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types |
31,892 |
27,336 |
$3.05M |
| 88175 |
Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer |
45,658 |
38,566 |
$2.87M |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
16,824 |
5,821 |
$2.55M |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
2,529 |
2,277 |
$2.45M |
| 96375 |
Therapeutic injection; each additional sequential IV push |
7,550 |
3,264 |
$2.39M |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
4,652 |
3,612 |
$2.39M |
| G0378 |
Hospital observation service, per hour |
1,402 |
1,265 |
$2.34M |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
61,718 |
47,834 |
$2.19M |
| 76815 |
Ultrasound, pregnant uterus, real time with image documentation, limited |
10,667 |
6,465 |
$2.09M |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
61,794 |
46,862 |
$2.08M |
| 76816 |
Ultrasound, pregnant uterus, real time with image documentation, follow-up |
21,407 |
15,787 |
$2.08M |
| 99218 |
|
1,297 |
517 |
$2.08M |
| 59025 |
Fetal non-stress test |
9,721 |
5,266 |
$1.94M |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
29,048 |
24,676 |
$1.90M |
| 76830 |
Ultrasound, transvaginal |
6,702 |
5,778 |
$1.77M |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
12,757 |
10,846 |
$1.66M |
| 76856 |
Ultrasound, pelvic (nonobstetric), real time with image documentation; complete |
6,569 |
5,663 |
$1.59M |
| 86803 |
|
18,718 |
16,004 |
$1.59M |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
19,017 |
15,232 |
$1.59M |
| 87480 |
|
21,175 |
18,316 |
$1.51M |
| 86850 |
|
25,772 |
21,099 |
$1.48M |
| 76805 |
Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation |
6,251 |
5,185 |
$1.47M |
| 84443 |
Thyroid stimulating hormone (TSH) |
16,166 |
13,630 |
$1.36M |
| J9271 |
Injection, pembrolizumab, 1 mg |
115 |
89 |
$1.25M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
15,360 |
7,501 |
$1.22M |
| 76811 |
Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed |
6,470 |
5,384 |
$1.21M |
| 86780 |
|
27,725 |
23,525 |
$1.20M |
| 76801 |
|
8,181 |
6,645 |
$1.14M |
| 86901 |
|
25,880 |
21,166 |
$1.12M |
| 86900 |
|
25,870 |
21,158 |
$1.12M |
| 87660 |
|
21,054 |
18,167 |
$1.11M |
| 76817 |
Ultrasound, pregnant uterus, real time with image documentation, transvaginal |
8,539 |
6,568 |
$1.11M |
| 84702 |
|
15,824 |
10,568 |
$1.08M |
| 87340 |
|
18,428 |
15,618 |
$1.05M |
| 87150 |
|
12,518 |
10,459 |
$1.03M |
| 86762 |
|
12,389 |
10,442 |
$979K |
| 81001 |
|
26,718 |
21,961 |
$959K |
| 87510 |
|
17,913 |
15,216 |
$908K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
2,394 |
1,869 |
$902K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
20,246 |
16,438 |
$827K |
| Q5117 |
Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg |
177 |
118 |
$777K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
4,622 |
2,288 |
$776K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
13,877 |
12,292 |
$747K |
| 96417 |
|
2,825 |
1,323 |
$739K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
7,936 |
6,731 |
$732K |
| J7050 |
Infusion, normal saline solution, 250 cc |
8,190 |
3,503 |
$697K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
9,728 |
6,165 |
$662K |
| 81025 |
|
7,750 |
6,222 |
$644K |
| 82728 |
|
8,394 |
7,507 |
$640K |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
5,646 |
2,457 |
$639K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
4,619 |
2,245 |
$638K |
| 80061 |
Lipid panel |
9,999 |
8,745 |
$613K |
| 86481 |
|
3,924 |
3,808 |
$583K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
3,775 |
1,311 |
$535K |
| J7307 |
Etonogestrel (contraceptive) implant system, including implant and supplies |
784 |
457 |
$505K |
| 82105 |
|
13,005 |
11,611 |
$490K |
| 76642 |
|
5,194 |
4,425 |
$486K |
| 87088 |
|
12,843 |
11,141 |
$469K |
| 86787 |
|
5,005 |
4,338 |
$445K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
2,832 |
1,870 |
$444K |
| J1726 |
Injection, hydroxyprogesterone caproate, (makena), 10 mg |
642 |
64 |
$437K |
| 77066 |
Tomosynthesis, mammo |
2,638 |
2,234 |
$430K |
| J2469 |
Injection, palonosetron hcl, 25 mcg |
1,970 |
785 |
$430K |
| 36415 |
Collection of venous blood by venipuncture |
7,103 |
6,120 |
$425K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
9,894 |
7,759 |
$418K |
| 81220 |
CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants |
1,302 |
1,086 |
$412K |
| 96415 |
|
1,508 |
865 |
$410K |
| 82962 |
|
2,601 |
1,555 |
$398K |
| 82677 |
|
5,989 |
4,925 |
$385K |
| 86480 |
|
3,592 |
2,642 |
$373K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
4,017 |
2,006 |
$369K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
2,593 |
1,501 |
$369K |
| J1439 |
Injection, ferric carboxymaltose, 1 mg |
504 |
343 |
$353K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
3,936 |
3,445 |
$346K |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
8,745 |
8,433 |
$345K |
| J3490 |
Unclassified drugs |
3,558 |
1,497 |
$325K |
| 77065 |
Tomosynthesis, mammo |
2,417 |
1,979 |
$318K |
| 88307 |
|
2,995 |
2,482 |
$317K |
| 82565 |
|
9,013 |
6,698 |
$311K |
| 80050 |
General health panel |
3,159 |
2,832 |
$301K |
| 80076 |
|
9,903 |
7,115 |
$296K |
| 96040 |
|
3,890 |
3,099 |
$293K |
| 76813 |
|
2,427 |
2,026 |
$289K |
| 58661 |
|
99 |
79 |
$285K |
| 85027 |
|
6,793 |
5,543 |
$285K |
| 80053 |
Comprehensive metabolic panel |
7,384 |
6,229 |
$283K |
| 87210 |
|
5,744 |
4,608 |
$281K |
| 82950 |
|
11,159 |
9,357 |
$280K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
7,070 |
5,610 |
$268K |
| 82607 |
|
4,249 |
3,761 |
$265K |
| 88342 |
|
1,493 |
995 |
$262K |
| 76825 |
|
792 |
531 |
$262K |
| 83735 |
|
6,349 |
4,290 |
$260K |
| S0028 |
Injection, famotidine, 20 mg |
2,010 |
850 |
$258K |
| 83021 |
|
3,313 |
2,614 |
$256K |
| 86870 |
|
1,139 |
494 |
$252K |
| 76820 |
|
2,783 |
1,161 |
$248K |
| 87186 |
|
5,358 |
4,493 |
$245K |
| J1642 |
Injection, heparin sodium, (heparin lock flush), per 10 units |
3,674 |
1,511 |
$239K |
| 96402 |
|
2,298 |
1,705 |
$237K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
2,665 |
2,112 |
$229K |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
1,764 |
1,143 |
$226K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
1,017 |
887 |
$224K |
| 87070 |
|
5,648 |
4,931 |
$220K |
| J2704 |
Injection, propofol, 10 mg |
1,486 |
971 |
$217K |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
1,718 |
1,118 |
$214K |
| 81229 |
|
151 |
82 |
$211K |
| 84450 |
|
6,561 |
5,198 |
$200K |
| C8908 |
Magnetic resonance imaging without contrast followed by with contrast, breast; bilateral |
233 |
217 |
$196K |
| 84100 |
|
5,480 |
3,679 |
$195K |
| 88141 |
|
4,990 |
4,481 |
$193K |
| J9202 |
Goserelin acetate implant, per 3.6 mg |
205 |
186 |
$193K |
| 83550 |
|
4,053 |
3,563 |
$191K |
| 81003 |
|
3,665 |
2,818 |
$188K |
| 58571 |
|
68 |
27 |
$187K |
| 86336 |
|
5,993 |
4,932 |
$182K |
| 92579 |
|
1,977 |
1,564 |
$181K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
4,417 |
2,637 |
$181K |
| 83001 |
|
2,197 |
1,969 |
$174K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
1,122 |
987 |
$171K |
| 51729 |
|
396 |
328 |
$171K |
| 59430 |
|
1,243 |
847 |
$170K |
| 83020 |
|
1,166 |
1,136 |
$167K |
| 82570 |
|
5,691 |
4,503 |
$166K |
| 84460 |
|
4,893 |
3,995 |
$166K |
| 84146 |
|
1,932 |
1,684 |
$161K |
| 84439 |
|
4,071 |
3,401 |
$159K |
| 92587 |
|
1,748 |
1,315 |
$159K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
1,631 |
903 |
$156K |
| 58300 |
|
463 |
301 |
$155K |
| 83615 |
|
5,266 |
3,667 |
$152K |
| 87077 |
|
4,550 |
3,763 |
$149K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
1,092 |
773 |
$149K |
| 88341 |
|
860 |
573 |
$148K |
| 80051 |
|
4,126 |
2,918 |
$143K |
| 93975 |
|
814 |
479 |
$142K |
| 82670 |
|
915 |
888 |
$141K |
| 84156 |
|
5,520 |
4,208 |
$140K |
| J7297 |
Levonorgestrel-releasing intrauterine contraceptive system (liletta), 52 mg |
197 |
170 |
$134K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
2,821 |
2,386 |
$133K |
| 36416 |
|
304 |
255 |
$131K |
| 82951 |
|
2,589 |
2,252 |
$126K |
| 84163 |
|
3,954 |
3,205 |
$123K |
| 99429 |
|
124 |
84 |
$116K |
| A4315 |
Insertion tray with drainage bag with indwelling catheter, foley type, two-way, all silicone |
647 |
386 |
$115K |
| 85610 |
|
2,477 |
1,579 |
$113K |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
1,027 |
664 |
$112K |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
1,234 |
641 |
$111K |
| 58301 |
|
350 |
251 |
$110K |
| 84520 |
|
4,433 |
3,180 |
$109K |
| 81002 |
|
9,292 |
6,254 |
$109K |
| 82746 |
|
1,709 |
1,509 |
$108K |
| J0185 |
Injection, aprepitant, 1 mg |
356 |
166 |
$108K |
| 82310 |
|
4,295 |
3,102 |
$107K |
| 96367 |
|
624 |
424 |
$107K |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
1,097 |
630 |
$97K |
| 93325 |
|
745 |
526 |
$97K |
| J1050 |
Injection, medroxyprogesterone acetate, 1 mg |
3,165 |
2,519 |
$93K |
| 97802 |
|
788 |
468 |
$91K |
| 96112 |
|
453 |
383 |
$90K |
| 76827 |
|
737 |
506 |
$90K |
| 86304 |
|
1,415 |
1,113 |
$88K |
| 92567 |
|
2,257 |
1,775 |
$88K |
| Q0138 |
Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) |
85 |
61 |
$88K |
| 82248 |
|
5,937 |
3,339 |
$88K |
| 71260 |
Computed tomography, thorax, diagnostic; with contrast material |
345 |
296 |
$80K |
| 86706 |
|
1,496 |
1,268 |
$80K |
| 85730 |
|
1,323 |
859 |
$79K |
| H0035 |
Mental health partial hospitalization, treatment, less than 24 hours |
181 |
27 |
$79K |
| 19083 |
|
90 |
70 |
$79K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
372 |
360 |
$78K |
| 82247 |
|
5,668 |
3,145 |
$77K |
| 84403 |
|
949 |
875 |
$76K |
| J0330 |
Injection, succinylcholine chloride, up to 20 mg |
443 |
289 |
$74K |
| 98960 |
|
488 |
302 |
$72K |
| 86920 |
|
607 |
350 |
$72K |
| 83013 |
|
560 |
325 |
$71K |
| 84703 |
|
1,121 |
911 |
$71K |
| 84481 |
|
638 |
615 |
$67K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
181 |
102 |
$64K |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
475 |
236 |
$63K |
| 96376 |
|
618 |
263 |
$61K |
| 51797 |
|
341 |
276 |
$59K |
| C9463 |
Injection, aprepitant, 1 mg |
182 |
13 |
$58K |
| J7040 |
Infusion, normal saline solution, sterile (500 ml = 1 unit) |
832 |
224 |
$58K |
| J9267 |
Injection, paclitaxel, 1 mg |
491 |
135 |
$57K |
| A9575 |
Injection, gadoterate meglumine, 0.1 ml |
660 |
490 |
$57K |
| 76641 |
|
270 |
220 |
$52K |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
1,261 |
1,140 |
$52K |
| J1756 |
Injection, iron sucrose, 1 mg |
612 |
121 |
$52K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
522 |
238 |
$50K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
860 |
657 |
$49K |
| 82465 |
|
2,137 |
1,751 |
$48K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
396 |
195 |
$46K |
| 84550 |
|
1,944 |
1,485 |
$45K |
| 84402 |
|
491 |
467 |
$43K |
| 82947 |
|
2,325 |
1,729 |
$41K |
| 97803 |
|
571 |
437 |
$39K |
| J0665 |
Injection, bupivicaine, not otherwise specified, 0.5 mg |
186 |
182 |
$39K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
63 |
44 |
$39K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
397 |
311 |
$37K |
| 77080 |
|
459 |
355 |
$37K |
| 83690 |
|
676 |
458 |
$35K |
| 86140 |
|
1,422 |
1,218 |
$31K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
766 |
201 |
$30K |
| 87522 |
Neg quan hep c or qual rna |
149 |
84 |
$30K |
| 82043 |
|
1,734 |
1,587 |
$30K |
| 97112 |
Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination |
418 |
212 |
$30K |
| 81479 |
Unlisted molecular pathology procedure |
73 |
71 |
$29K |
| 87255 |
|
411 |
306 |
$28K |
| 82378 |
|
391 |
365 |
$28K |
| 90847 |
Family psychotherapy with the patient present, 50 minutes |
743 |
579 |
$28K |
| 82952 |
|
2,320 |
2,053 |
$27K |
| 82239 |
|
693 |
454 |
$26K |
| 77062 |
|
128 |
123 |
$25K |
| 85652 |
|
1,701 |
1,479 |
$25K |
| 86923 |
|
61 |
51 |
$24K |
| G0499 |
Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result |
324 |
307 |
$22K |
| 87081 |
|
730 |
577 |
$22K |
| J1170 |
Injection, hydromorphone, up to 4 mg |
192 |
87 |
$21K |
| 99396 |
Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years |
140 |
132 |
$20K |
| 83516 |
|
503 |
253 |
$19K |
| 57288 |
|
13 |
12 |
$19K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
271 |
252 |
$18K |
| 85018 |
|
457 |
384 |
$18K |
| 82784 |
|
298 |
152 |
$18K |
| 99215 |
Prolong outpt/office vis |
135 |
71 |
$17K |
| 90791 |
Psychiatric diagnostic evaluation |
111 |
66 |
$17K |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
252 |
114 |
$17K |
| J9045 |
Injection, carboplatin, 50 mg |
237 |
55 |
$17K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
162 |
161 |
$16K |
| J0694 |
Injection, cefoxitin sodium, 1 gm |
209 |
135 |
$15K |
| 86376 |
|
179 |
175 |
$15K |
| 90686 |
|
394 |
323 |
$15K |
| 89060 |
|
280 |
197 |
$14K |
| 92588 |
|
130 |
105 |
$14K |
| 88302 |
|
111 |
100 |
$14K |
| J2710 |
Injection, neostigmine methylsulfate, up to 0.5 mg |
12 |
12 |
$14K |
| 86300 |
|
227 |
205 |
$13K |
| 88300 |
|
27 |
27 |
$13K |
| J0134 |
Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg |
60 |
57 |
$12K |
| J3475 |
Injection, magnesium sulfate, per 500 mg |
137 |
67 |
$12K |
| 90674 |
|
306 |
290 |
$11K |
| 86696 |
|
248 |
195 |
$11K |
| 83002 |
|
173 |
156 |
$10K |
| 86618 |
|
198 |
188 |
$10K |
| 76376 |
|
84 |
83 |
$10K |
| 82550 |
|
366 |
345 |
$10K |
| J0690 |
Injection, cefazolin sodium, 500 mg |
35 |
25 |
$10K |
| 86704 |
|
238 |
185 |
$10K |
| 90792 |
Psychiatric diagnostic evaluation with medical services |
85 |
57 |
$10K |
| 86695 |
|
249 |
195 |
$10K |
| 83014 |
|
545 |
310 |
$9K |
| 82627 |
|
114 |
113 |
$9K |
| G0108 |
Diabetes outpatient self-management training services, individual, per 30 minutes |
222 |
193 |
$9K |
| 84478 |
|
260 |
254 |
$9K |
| 77061 |
|
60 |
60 |
$8K |
| 86694 |
|
177 |
130 |
$8K |
| 87075 |
|
170 |
104 |
$8K |
| 87581 |
|
68 |
45 |
$8K |
| J7060 |
5% dextrose/water (500 ml = 1 unit) |
52 |
25 |
$7K |
| 87205 |
|
255 |
167 |
$7K |
| 96366 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour |
51 |
26 |
$7K |
| 92550 |
|
200 |
119 |
$6K |
| A4648 |
Tissue marker, implantable, any type, each |
54 |
44 |
$6K |
| 83986 |
|
504 |
383 |
$6K |
| 83540 |
|
168 |
162 |
$6K |
| 90480 |
|
132 |
132 |
$6K |
| 86039 |
|
135 |
113 |
$5K |
| 92558 |
|
130 |
81 |
$5K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
110 |
66 |
$5K |
| 83721 |
|
188 |
168 |
$5K |
| 76882 |
|
87 |
76 |
$5K |
| 85046 |
|
249 |
210 |
$5K |
| 58340 |
|
40 |
40 |
$5K |
| 99152 |
|
51 |
34 |
$5K |
| 93976 |
|
34 |
16 |
$5K |
| 86709 |
|
114 |
51 |
$5K |
| 99201 |
|
112 |
95 |
$4K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
46 |
44 |
$4K |
| J1644 |
Injection, heparin sodium, per 1000 units |
164 |
27 |
$4K |
| 77049 |
|
12 |
12 |
$4K |
| 87430 |
|
147 |
75 |
$4K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
40 |
12 |
$4K |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
275 |
149 |
$4K |
| J2003 |
Injection, lidocaine hydrochloride, 1 mg |
14 |
14 |
$4K |
| 96523 |
|
85 |
66 |
$4K |
| 85384 |
|
269 |
66 |
$3K |
| 52000 |
|
13 |
13 |
$3K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
167 |
42 |
$3K |
| 87147 |
|
146 |
125 |
$3K |
| 0001A |
|
46 |
39 |
$3K |
| 85651 |
|
168 |
159 |
$3K |
| 51725 |
|
14 |
14 |
$3K |
| 87517 |
|
33 |
13 |
$3K |
| 84144 |
|
25 |
25 |
$3K |
| 57454 |
|
13 |
13 |
$2K |
| 87486 |
|
26 |
17 |
$2K |
| 86735 |
|
29 |
29 |
$2K |
| 83970 |
|
13 |
12 |
$2K |
| G0109 |
Diabetes outpatient self-management training services, group session (2 or more), per 30 minutes |
117 |
55 |
$2K |
| 84425 |
|
36 |
36 |
$2K |
| 90472 |
Immunization administration, each additional vaccine (list separately) |
65 |
59 |
$2K |
| 11982 |
|
12 |
12 |
$2K |
| 86765 |
|
27 |
27 |
$2K |
| 71046 |
Radiologic examination, chest; 2 views |
25 |
24 |
$2K |
| 84436 |
|
91 |
88 |
$2K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
14 |
14 |
$2K |
| 92585 |
|
13 |
13 |
$2K |
| 0002A |
|
39 |
32 |
$2K |
| 92593 |
|
45 |
14 |
$2K |
| 58100 |
|
12 |
12 |
$1K |
| 86705 |
|
26 |
26 |
$1K |
| J2790 |
Injection, rho d immune globulin, human, full dose, 300 micrograms (1500 i.u.) |
16 |
12 |
$1K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
20 |
12 |
$1K |
| 84075 |
|
52 |
27 |
$1K |
| J0702 |
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg |
191 |
38 |
$1K |
| 83520 |
|
16 |
13 |
$960.14 |
| G0145 |
Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision |
273 |
248 |
$912.22 |
| 82120 |
|
27 |
24 |
$766.14 |
| 85014 |
|
48 |
41 |
$735.52 |
| V5264 |
Ear mold/insert, not disposable, any type |
32 |
25 |
$725.73 |
| 82652 |
|
13 |
12 |
$669.53 |
| 99153 |
Mod sedat endo service >5yrs |
22 |
17 |
$642.98 |
| J2550 |
Injection, promethazine hcl, up to 50 mg |
121 |
48 |
$640.55 |
| J1453 |
Injection, fosaprepitant, 1 mg |
15 |
12 |
$547.68 |
| 84132 |
|
47 |
43 |
$488.87 |
| 86431 |
|
36 |
29 |
$457.80 |
| 82150 |
|
17 |
17 |
$299.59 |
| 90661 |
|
19 |
19 |
$109.64 |
| J3420 |
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg |
39 |
24 |
$16.21 |
| J2370 |
Injection, phenylephrine hcl, up to 1 ml |
41 |
13 |
$0.00 |